| 產(chǎn)品編號 | bs-0580R |
| 英文名稱 | SOCS3 Rabbit pAb |
| 中文名稱 | 細胞因子信號傳導抑制蛋白3抗體 |
| 別 名 | suppressor of cytokine signaling 3; ATOD4; CIS 3; CIS3; Cish3; Cytokine induced SH2 protein 3; E2a Pbx1 target gene in fibroblasts 10; EF 10; MGC71791; SOCS 3; SOCS-3; SSI 3; SSI3; STAT induced STAT inhibitor 3; Suppressor of cytokine signaling 3; SOCS3_HUMAN. |
 |
Specific References (6) | bs-0580R has been referenced in 6 publications.
[IF=7.666] Monika Bednarczyk. et al. β2 Integrins on Dendritic Cells Modulate Cytokine Signaling and Inflammation-Associated Gene Expression, and Are Required for Induction of Autoimmune Encephalomyelitis. CELLS-BASEL. 2022 Jan;11(14):2188 IF ; Mouse.
[IF=2.559] Bi?J et al. PPARγ alleviated hepatocyte steatosis through reducing SOCS3 by inhibiting JAK2/STAT3 pathway. Biochem Biophys Res Commun. 2018 Apr 15;498(4):1037-1044. ICC&WB ; Rat.
[IF=2.41] Liu, Wen-bin, et al. "CpG island hypermethylation of multiple tumor suppressor genes associated with loss of their protein expression during rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine." Biochemical and biophysical research communications 402.3 (2010): 507. IHC-P ; Rat.
[IF=2.33] Zhu, Jian-guo, et al. "Expression of SOCSs in human prostate cancer and their association in prognosis." Molecular and cellular biochemistry (2013): 1-9. Human.
[IF=1.96] Kou, Wei, et al. "Transforming growth factor-β1 promotes Treg commitment in nasal polyposis after intranasal steroid treatment." Inflammation Research (2013): 1-7. ELISA ; Human.
[IF=1.55] Song, Jin-Ning, et al. "Dynamic expression of the suppressor of cytokine signaling-3 and cytokines in the cerebral basilar artery of rats with subarachnoid hemorrhage, and the effect of acetylcholine." Acta Neurochirurgica (2014): 1-9. IHC-P ; Rat.
|
| 研究領(lǐng)域 | 細胞生物 免疫學 神經(jīng)生物學 信號轉(zhuǎn)導 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 克 隆 號 | |
| 交叉反應(yīng) | Human,Mouse,Rat (predicted: Rabbit,Pig,Sheep,Cow,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,Flow-Cyt=1ug/Tes
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 25 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Socs3: 155-225/225 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Cytokines signal transduction pathway suppressor of cytokine signaling 3 positive cells in the brain are widely distributed, some of the cytoplasm of neurons, nerve fibers, glial cell line. suppressor of cytokine signaling 3 studies in recent years to prove: vascular endothelial cells also showed immune SOCS 3-positive. Function: SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo (By similarity). Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST (By similarity). Subunit: Interacts with multiple activated proteins of the tyrosine kinase signaling pathway including IGF1 receptor, insulin receptor and JAK2. Binding to JAK2 is mediated through the KIR and SH2 domains to a phosphorylated tyrosine residue within the JAK2 JH1 domain. Binds specific activated tyrosine residues of the leptin, EPO, IL12, GSCF and gp130 receptors. Interaction with CSNK1E stabilizes SOCS3 protein. Component of the probable ECS(SOCS3) E3 ubiquitin-protein ligase complex which contains CUL5, RNF7/RBX2, Elongin BC complex and SOCS3. Interacts with CUL5, RNF7, TCEB1 and TCEB2. Interacts with CUL2. Tissue Specificity: Widely expressed with high expression in heart, placenta, skeletal muscle, peripheral blood leukocytes, fetal and adult lung, and fetal liver and kidney. Lower levels in thymus. Post-translational modifications: Phosphorylated on tyrosine residues after stimulation by the cytokines, IL-2, EPO or IGF1. DISEASE: Genetic variation in the promoter region of SOCS3 may be associated with susceptibility to atopic dermatitis 4 (ATOD4) [MIM:605805]. Atopic dermatitis [MIM:603165], also known as eczema commonly begins in infancy or early childhook and is characterized by ichy and inflamed skin. Similarity: Contains 1 SH2 domain. Contains 1 SOCS box domain. SWISS: O14543 Gene ID: 9021 Database links: Entrez Gene: 9021 Human Omim: 604176 Human SwissProt: O14543 Human Unigene: 527973 Human Unigene: 127801 Rat 細胞因子信號轉(zhuǎn)導途徑抑制蛋白SOCS3陽性細胞在腦內(nèi)分布廣泛,陽性產(chǎn)物主要神經(jīng)元核內(nèi);部分神經(jīng)元的胞漿、神經(jīng)纖維、膠質(zhì)細胞。 細胞激酶信號-3抑制劑近年研究證明：血管內(nèi)皮細胞也呈SOCS 3免疫陽性. |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Heart (Mouse) Lysate at 40 ug
Lane 2: Kidney (Mouse) Lysate at 40 ug
Lane 3: Cerebrum (Rat) Lysate at 40 ug
Lane 4: Lymph node (Rat) Lysate at 40 ug
Primary: Anti-SOCS3 (bs-0580R) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 23-27 kD
Observed band size: 27/23 kD
Blank control:U937.
Primary Antibody (green line): Rabbit Anti-SOCS3 antibody (bs-0580R)
Dilution: 1ug/Test;
Secondary Antibody : Goat anti-rabbit IgG-FITC
Dilution: 0.5ug/Test.
Protocol
The cells were fixed with 4% PFA (10min at room temperature)and then permeabilized with 0.1% PBST for 20 min at room temperature.The cells were then incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復(fù)方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設(shè)計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
